Taro Pharmaceuticals USA clinical trials

Acquired by Sun Pharmaceutical Industries Limited, Sep 20, 2010 · source ↗

The registry lists 71 studies whose lead sponsor is Taro Pharmaceuticals USA. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 10, 2025.

Studies

Recruiting first, then most recently updated. Showing 50 of 71. List all 71 → · All Sun Pharmaceutical Industries Limited studies →

• Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne VulgarisCompletedNCT04321070Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne VulgarisCompletedNCT06733402Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.CompletedNCT06673641Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.CompletedNCT06673654Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical GelCompletedNCT03094403Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.CompletedNCT06305637Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne VulgarisCompletedNCT06063473Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque PsoriasisCompletedNCT02340169Phase 4

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• An Open-Label Study to Assess SafetyCompletedNCT03645499Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.CompletedNCT05282771Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Oxymetazoline 1% Cream to RHOFADECompletedNCT05148689Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne VulgarisCompletedNCT04883736Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.CompletedNCT04883593Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne VulgarisCompletedNCT04724473Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne VulgarisCompletedNCT04797793Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% CreamCompletedNCT04358770Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne VulgarisCompletedNCT04134273Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.CompletedNCT01876550Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp PsoriasisCompletedNCT03880357Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial RosaceaCompletedNCT03689010Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical ProductCompletedNCT02933502Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque PsoriasisCompletedNCT02618759Phase 3

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic DermatitisCompletedNCT02595073Phase 3

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.CompletedNCT02932891Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque PsoriasisCompletedNCT02601469Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic DermatitisCompletedNCT02595008Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp PsoriasisCompletedNCT02932462Phase 3

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Phase III Clinical Study in Patients With Mild to Severe Scalp PsoriasisCompletedNCT02933866Phase 3

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical StudyCompletedNCT02413229Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• An Open Label, Safety Study to Assess the Potential for Adrenal SuppressionCompletedNCT02932878Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXSCompletedNCT02933528Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Efficacy Study in Patients With Acne Vulgaris.CompletedNCT02935036Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe NailCompletedNCT02343627Phase 2

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea PedisCompletedNCT02335255Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%CompletedNCT03257943Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne VulgarisCompletedNCT02578043Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne VulgarisCompletedNCT03433378Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne VulgarisCompletedNCT03427554Early Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque PsoriasisCompletedNCT01206387Phase 3

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted the day Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea PedisCompletedNCT02132260Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne VulgarisCompletedNCT01769235Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea PedisCompletedNCT01580878Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne VulgarisCompletedNCT03132194Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne VulgarisCompletedNCT02929719Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne VulgarisCompletedNCT02595034Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne VulgarisCompletedNCT02709902Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne VulgarisCompletedNCT02411955Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne VulgarisCompletedNCT02411942Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne VulgarisCompletedNCT01742637Phase 1

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited

• Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head LiceCompletedNCT00752973Phase 2/3

  Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted before Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited